Barclays Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its target price increased by Barclays from $160.00 to $165.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other brokerages also recently issued reports on NBIX. Wedbush reaffirmed an “outperform” rating and issued a $148.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Raymond James reiterated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. HC Wainwright reissued a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, Royal Bank of Canada dropped their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $166.29.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $136.99 on Monday. Neurocrine Biosciences has a 1 year low of $110.95 and a 1 year high of $157.98. The company has a market capitalization of $13.87 billion, a price-to-earnings ratio of 36.73 and a beta of 0.34. The business has a 50-day moving average of $124.40 and a two-hundred day moving average of $130.59.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp boosted its position in Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock worth $99,000 after purchasing an additional 92 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Neurocrine Biosciences by 1.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock worth $128,639,000 after buying an additional 13,069 shares in the last quarter. Burney Co. grew its stake in Neurocrine Biosciences by 4.1% in the 2nd quarter. Burney Co. now owns 82,578 shares of the company’s stock valued at $11,369,000 after acquiring an additional 3,236 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Neurocrine Biosciences by 41.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 90,018 shares of the company’s stock valued at $12,393,000 after acquiring an additional 26,195 shares in the last quarter. Finally, Innealta Capital LLC acquired a new position in Neurocrine Biosciences during the second quarter worth about $30,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.